The Soy Isoflavones for Reducing Bone Loss (SIRBL) study: A 3-y randomized controlled trial in postmenopausal women

American Journal of Clinical Nutrition

Volumn 91, Issue 1, 2010, Pages 218-230

  Alekel, D Lee ^a   Van Loan, Marta D ^c   Koehler, Kenneth J ^b   Hanson, Laura N ^a   Stewart, Jeanne W ^a   Hanson, Kathy B ^a   Kurzer, Mindy S ^d   Petersone, C Theodore ^b  

^a IOWA STATE UNIVERSITY   (United States)

^b E005A Lagomarcino Hall   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCIUM; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; COLECALCIFEROL; ISOFLAVONE; MAGNESIUM; NOVASOY; PHOSPHORUS; PLACEBO; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; ISOFLAVONE DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY FAT DISTRIBUTION; BODY WEIGHT; BONE DENSITY; CALCIUM INTAKE; CALCIUM URINE LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; FEMALE; FEMUR; FEMUR NECK; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LUMBAR SPINE; MAGNESIUM URINE LEVEL; MULTICENTER STUDY; NORMAL HUMAN; OSTEOLYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; POSTMENOPAUSE; POTASSIUM URINE LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; UNSPECIFIED SIDE EFFECT; URINE LEVEL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; DRUG EFFECT; LIFESTYLE; MIDDLE AGED; OSTEOPOROSIS; PATIENT SELECTION; PHYSIOLOGY; QUESTIONNAIRE; SOYBEAN; TABLET; UNITED STATES;

AGED; BONE DENSITY; CALCIUM; CALIFORNIA; CHOLECALCIFEROL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IOWA; ISOFLAVONES; LIFE STYLE; MIDDLE AGED; OSTEOPOROSIS; PATIENT SELECTION; POSTMENOPAUSE; QUESTIONNAIRES; SOYBEANS; TABLETS;

EID: 74049090888     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.3945/ajcn.2009.28306     Document Type: Article

References (67)

1. Santoro N. Symptoms of menopause: hot flushes. Clin Obstet Gynecol 2008;51:539-48.
2. Jackson RD, Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Curr Osteoporos Rep 2007; 5:153-9.
3. Beresford SAA, Weiss NS, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997;349:458-61.
4. Manson JE, Hsia J, Johnson KC, et al; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.
5. Rossouw JF, Anderson GL, Prentice, et al; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33.
6. Scharbo-DeHaan M. Hormone replacement therapy. Nurse Pract 1996; 21:1-13.
7. Setchell KD, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999;129:758S-67S.
8. Niculescu MD, Pop EA, Fischer LM, Zeisel SH. Dietary isoflavones differentially induce gene expression changes in lymphocytes from postmenopausal women who form equol as compared with those who do not. J Nutr Biochem 2007;18:380-90.
9. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17: 353-81.
10. Alekel DL, St Germain A, Peterson CT, Hanson KB, Stewart JW, Toda T. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am J Clin Nutr 2000;72:844-52.
11. Somekawa Y, Chiguchi M, Ishibashi T, Aso T. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol 2001;97:109-15.
12. Zhang X, Shu XO, Li H, et al. Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 2005;165:1890-5.
13. Song Y, Paik HY, Joung H. Soybean and soy isoflavone intake indicate a positive change in bone mineral density for 2 years in young Korean women. Nutr Res 2008;28:25-30.
14. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW Jr. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 1998;68(suppl):1375S-9S.
15. Marini H, Minutoli L, Polito F, et al. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. Ann Intern Med 2007;146:839-47.
16. Ye Y-B, Tang X-Y, Verbruggen MA, Su Y-X. Soy isoflavones attenuate bone loss in early postmenopausal Chinese women: a single-blind randomized, placebo-controlled trial. Eur J Nutr 2006;45:327-34.
17. Arjmandi BH, Lucas EA, Khalil DA, et al. One year soy protein supplementation has positive effects on bone formation markers but not bone density in postmenopausal women. Nutr J 2005;4:8-17.
18. Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. Menopause 2004;11:290-8.
19. Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 2004;292:65-74.
20. Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F. Longterm consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study. Am J Clin Nutr 2008;87:761-70.
21. Vupadhyayula PM, Gallagher JC, Templin T, Logsdon SM, Smith LM. Effects of soy protein isolate on bone mineral density and physical performance indices in postmenopausal women: a 2-year randomized, double-blind, placebo-controlled trial. Menopause 2009;16:320-8.
22. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004;82:145-8.
23. Messina MJ, Wood CJ. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J 2008;7:17-28.
24. Vatanparast H, Chilibeck PD. Does the effect of soy phytoestrogens on bone in postmenopausal women depend on the equol-producing phenotype? Nutr Rev 2007;65:294-9.
25. Nielsen NR, Grønbaek M. Interactions between intakes of alcohol and postmenopausal hormones on risk of breast cancer. Int J Cancer 2008;122: 1109-13.
26. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 1998;8:468-89.
27. Food and Nutrition Board. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: Institute of Medicine, National Academy Press, 1999.
28. Alekel DL. Contributions of physical activity, body composition, age, and nutritional factors to total and regional bone mass in premenopausal aerobic dancers and exercisers. PhD dissertation. University of Illinois-Urbana, Urbana, IL, 1993.
29. MorabiaA, CostanzaMC. International variability in ages atmenarche, first live birth, andmenopause:WorldHealthOrganization collaborative study of neoplasia and steroid contraceptives. Am J Epidemiol 1998;148:1195-205.
30. St Germain A, Peterson CT, Robinson J, Alekel DL. Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 2001;8:17-26.
31. Kirk P, Patterson RE, Lampe J. Development of a soy food frequency questionnaire to estimate isoflavone consumption in U.S. adults. J Am Diet Assoc 1999;99:558-63.
32. Franke AA, Custer LJ, Wilkens LR, et al. Liquid chromatographic- photodiode array mass spectrometric analysis of dietary phytoestrogens from human urine and blood. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:45-59.
33. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4.
34. Pines A, Katchman H, Villa Y, et al. The effect of various hormonal preparations and calcium supplementation on bone mass in early menopause. Is there a predictive value for the initial bone density and body weight? J Intern Med 1999;246:357-61.
35. Allison PD. Multicollinearity. In: Logistic regression using the SAS system-theory and application. Cary, NC: SAS Institute, Inc, 1999.
36. Hollis BW. Measuring 25(OH)vitamin D in a clinical environment: challenges and needs. Am J Clin Nutr 2008;88:507S-10S.
37. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006; 84:18-28. (Published erratum appears in Am J Clin Nutr 2006;84:1253.)
38. Stewart JW, Alekel DL, Ritland LM, Van Loan M, Gertz E, Genschel U. Serum 25(OH) vitamin D is related to indicators of overall physical fitness in healthy postmenopausal women. Menopause (in press).
39. Bair YA, Gold EB, Zhang G, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause 2008;15:32-43.
40. Ho SC, Bacon E, Harris T, Looker A, Muggi S. Hip fracture rates in Hong Kong and the United States, 1988 through 1989. Am J Public Health 1993;83:694-7.
41. Ross PD, Norimatsu H, Davis JW, et al. A comparison of hip fracture incidence among native Japanese, Japanese Americans, and American Caucasians. Am J Epidemiol 1991;133:801-9.
42. Fujita T, Yoshikawa S, Ono K, Inoue T, Orimo H. Usefulness of TC-80 (ipriflavone) tablets in osteoporosis: multi-center, double-blind placebo-controlled study. Igaku Noayumi 1986;138:113-41.
43. Alexandersen P, Toussaint A, Christiansen C, et al. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. JAMA 2001;285:1482-8.
44. Markiewicz L, Garey J, Adlercreutz H, Gurpide E. In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 1993;45: 399-405.
45. Song TT, Hendrich S, Murphy PA. Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem 1999;47:1607-10.
46. Breslau NA, Brinkley L, Hill KD, Pak CY. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism. J Clin Endocrinol Metab 1988;66:140-6.
47. Dalais FS, Rice GE, Wahlqvist ML, et al. Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1998;1:124-9.
48. Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss: a 2 year randomized, placebo-controlled trial. Eur J Nutr 2004;43:246-57.
49. Evans EM, Racette SB, Van Pelt RE, Peterson LR, Villareal DT. Effects of soy protein isolate and moderate exercise on bone turnover and bone mineral density in postmenopausal women. Menopause 2007;14:481-8.
50. Newton KM, LaCroix AZ, Levy L, et al. Soy protein and bone mineral density in oldermenandwomen: a randomized trial.Maturitas 2006;55:270-7.
51. Greendale GA, FitzGerald G, Huang MH, et al. Dietary soy isoflavones and bone mineral density: results from the study of women's health across the nation. Am J Epidemiol 2002;155:746-54.
52. Kritz-Silverstein D, Goodman-Gruen DL. Usual dietary isoflavone intake, bone mineral density, and bone metabolism in postmenopausal women. J Womens Health Gend Based Med 2002;11:69-78.
53. Ho SC,Woo J, Lam S, Chen Y, Sham A, Lau J. Soy protein consumption and bone mass in early postmenopausal Chinese women. Osteoporos Int 2003;14:835-42.
54. Ikeda Y, Iki M, Morita A, et al. Intake of fermented soybeans, natto, is associated with reduced bone loss in postmenopausal women: Japanese Population-Based Osteoporosis (JPOS) Study. J Nutr 2006;136:1323-8.
55. Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind, randomized, controlled trial. J Clin Endocrinol Metab 2003;88:4740-7.
56. Morabito N, Crisafulli A, Vergara C, et al. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. J Bone Miner Res 2002;17:1904-12.
57. Messina M, Ho S, Alekel DL. Skeletal benefits of soy isoflavones: a review of the clinical trial and epidemiologic data. Curr Opin Clin Nutr Metab Care 2004;7:649-58.
58. Alekel DL. Skeletal effects of soy isoflavones in humans: bone mineral density and bone markers. In: Wildman REC, ed. Handbook of nutraceuticals and functional foods. 2nd ed. Boca Raton, FL: CRC Press LLC, 2006.
59. Heaney RP. The bone-remodeling transient: implications for the interpretation of clinical studies of bone mass change. J Bone Miner Res 1994;9:1515-23.
60. Salaffi F, Silveri F, Stancati A, Grassi W. Development and validation of the osteoporosis prescreening risk assessment (OPERA) tool to facilitate identification of women likely to have low bone density. Clin Rheumatol 2005;24:203-11.
61. Jürimäe J, Jürimäe T, Leppik A, Kums T. The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy post-menopausal women. J Bone Miner Metab 2008;26:618-23.
62. Łukaszkiewicz J, Karczmarewicz E, Płudowski P, et al. EPOLOS Group. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study. Med Sci Monit 2008;14:PH65-70.
63. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD. Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab 1994;79:950-4.
64. Hsu YH, Venners SA, Terwedow HA, et al. Relation of body composition, fat mass, and serum lipids to osteoporotic fractures and bone mineral density in Chinese men and women. Am J Clin Nutr 2006;83:146-54.
65. Macdonald HM, New SA, Fraser WD, Campbell MK, Reid DM. Low dietary potassium intakes and high dietary estimates of net endogenous acid production are associated with low bone mineral density in premenopausal women and increased markers of bone resorption in postmenopausal women. Am J Clin Nutr 2005;81: 923-33.
66. Massey LK, Whiting SJ. Dietary salt, urinary calcium, and bone loss. J Bone Miner Res 1996;11:731-6.
67. Rafferty K, Heaney RP. Nutrient effects on the calcium economy: emphasizing the potassium controversy. J Nutr 2008;138:166S-71S.